• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or keep ADHD medications during pregnancy and nursing is a challenge for women suffering from the condition. There is a lack of information about how long-term exposure to these medications could affect the fetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological problems such as hearing loss or vision, febrile seizures or IQ impairment. The authors acknowledge the need for higher-quality studies.

Risk/Benefit Analysis

Women who are expecting and taking ADHD medication must evaluate the benefits of using it against the possible risks to the fetus. Doctors don't have enough data to give clear advice but they can provide information on risks and benefits to help pregnant women make an informed decision.

A study published in Molecular Psychiatry concluded that women who were taking common adhd medications medication during their early pregnancy did not have a higher risk of fetal malformations, or structural birth defects. Researchers used a vast population-based study of case-control to evaluate the incidence of major structural birth defects in infants born to mothers who had taken stimulants in early pregnancy, as well as those who had not. Pediatric cardiologists and clinical geneticists examined the cases to ensure an accurate classification of the cases and to reduce the possibility of bias.

However, the researchers' study had its limitations. The most important issue was that they were unable to separate the effects of the medication from the effects of the disorder at hand. This limitation makes it difficult to know whether the small differences observed in the groups that were exposed are due to medication use or confounding by comorbidities. The researchers also did not look at the long-term effects for the offspring.

The study did reveal that babies whose mothers had taken ADHD medications during pregnancy were at slightly higher risk of being admitted to the neonatal intensive care unit (NICU) than infants who were born without any medication or taken off their medication prior to or during pregnancy. The reason for this was central nervous system disorders. The increased risk of admission was not influenced by the stimulant medication that was used during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher likelihood of having to have a caesarean section or one whose baby scored low on the Apgar scale (less than 7). These increases appeared to be unrelated to the type of medication taken during pregnancy.

Researchers suggest that the small risks posed by the use of ADHD medication during pregnancies in the early stages may be offset by the more beneficial outcomes for both baby and mother of continued treatment for the woman’s disorder. Physicians should discuss the issue with their patients and, where possible, assist them in developing strategies for improving their coping skills which can adhd medication help with memory reduce the impact of her disorder on her daily life and relationships.

Interactions with Medication

Doctors are increasingly confronted with the dilemma of whether to keep treatment or stop during pregnancy as more women are diagnosed with ADHD. These decisions are usually made without clear and reliable evidence. Instead, doctors must weigh their own knowledge and experience, as well as the experiences of other physicians and the research on the subject.

Particularly, the subject of potential risks for the infant can be difficult. The research on this issue is based on observation instead of controlled studies and the results are contradictory. Most studies focus on live births, which can underestimate the severity of teratogenic effects which can cause terminations or abortions of pregnancy. The study discussed in this journal club addresses these shortcomings by looking at data from both live and deceased births.

The conclusion The conclusion: While some studies have found an association between ADHD medications and the risk of certain birth defects, other studies have not found any evidence of a link and the majority of studies have a neutral or slightly negative impact. In each case, a careful evaluation of the risks and benefits should be conducted.

For a lot of women with ADHD and ADD, the decision to discontinue medication can be difficult, if not impossible. In a recent article in Archives of Women's Mental Health by psychologist Jennifer Russell, she notes that stopping ADHD medications during pregnancy can cause depression and feelings of isolation. A decrease in medication could also impact the ability to drive safely and perform work-related tasks, which are crucial aspects of normal life for those with ADHD.

She suggests that women who are unsure whether to continue taking medication or discontinue it due to pregnancy, educate their family members, coworkers and friends about the condition, its effects on daily functioning, and the benefits of keeping the current treatment plan. It can also help women feel more confident in her decision. Certain medications can be passed through the placenta. If a woman decides to stop taking her ADHD medication while breastfeeding, it's important to be aware that the medication could be transferred to the baby.

Risk of Birth Defects

As the use of ADHD medication to treat the symptoms of attention deficit hyperactivity disorder (ADHD) grows, so do concerns over the impact that these medications could have on fetuses. Recent research published in the journal Molecular Psychiatry has added to the body of knowledge regarding this issue. Researchers used two huge data sets to study over 4.3 million pregnancies and determine if stimulant medication use increased birth defects. Although the risk overall remains low, the scientists discovered that the first-trimester exposure to ADHD medicines was associated with a slightly higher rate of certain heart defects like ventriculo-septal defects (VSD).

The researchers of the study didn't discover any link between the use of early medications and other congenital anomalies like facial deformities, or club feet. The findings are in line with previous studies showing the presence of a small, but significant increase in the risk of developing cardiac malformations in women who started taking ADHD medications prior to the time of pregnancy. This risk increased during the latter half of pregnancy when a large number of women began to stop taking their medication.

Women who took ADHD medication during the first trimester were more likely to need a caesarean or have a low Apgar after delivery and have a baby that needed help breathing at birth. However, the authors of the study were unable to eliminate bias due to selection by restricting the study to women who did not have other medical issues that could have contributed to the findings.

The researchers hope that their research will aid in the clinical decisions of doctors who see pregnant women. They suggest that although discussing the benefits and risks is important but the decision to stop or continue medication should be based on the woman's requirements and the severity of her ADHD symptoms.

The authors caution that, even though stopping the medication is a possibility to look into, it is not recommended due to the high prevalence of depression and other mental problems among women who are pregnant or have recently given birth. Furthermore, research suggests that women who choose to stop taking their medications are more likely to have difficulties adjusting to life without them after the baby's arrival.

Nursing

The responsibilities that come with being a new mom can be overwhelming. Women with ADHD who have to manage their symptoms while attending doctor appointments, getting ready for the arrival of their child and adjusting to new household routines may face a lot of challenges. Many women choose to continue taking their ADHD medication during pregnancy.

The majority of stimulant medications are absorbed through breast milk in very small amounts, therefore the risk to the infant who is breastfeeding is low. The amount of exposure to medications will differ based on dosage, frequency of administration and the time of the day. Additionally, different drugs enter the infant's system through the gastrointestinal tract or through breast milk. The effect on the health of a newborn isn't completely comprehended.

Because of the lack of research, some doctors might be tempted to stop taking stimulant medication during a woman's pregnancy. This is a complicated decision for the patient, who must balance the benefits of keeping her medication with the potential dangers to the embryo. Until more information is available, GPs should ask all pregnant patients about their experience with ADHD and if they are taking or planning to take medication during the perinatal time.

A growing number of studies have revealed that women can continue their mild Adhd medication medication while they are pregnant and nursing. This has led to many patients are choosing to do so and in consultation with their doctor they have discovered that the benefits of continuing their current medication far exceed any risk.

It's important for women with ADHD who are considering breastfeeding to seek out a specialist psychiatrist's advice prior to becoming pregnant. They should discuss their medication with their doctor and discuss the advantages and disadvantages of continued treatment, including non-pharmacological management strategies. Psychoeducation is also needed to help pregnant women suffering from concerta adhd medication recognize the signs and underlying disorder. They should also be educated about treatment options and reinforce strategies for coping. This should be a multidisciplinary approach with the GP doctors, obstetricians and psychiatrists. Pregnancy counseling should include a discussion of a treatment plan for the mother and child, and monitoring for signs of deterioration and, if needed adjustments to the medication regime.